Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Samsung Electronics | Eli Lilly and Company | NVIDIA | |
|---|---|---|---|
| Moat rating | narrow Samsung leads three of its four principal markets — Q1 2026 DRAM revenue share 38.5% ($37.32B, TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), Q1 2026 NAND share 31.6% ($13.51B, TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html), and #1 in Q2 2026 smartphones at 24% (Counterpoint via Android Authority, https://www.androidauthority.com/counterpoint-research-q2-2026-smartphone-shipment-report-3686931/) — but the moat is narrow, not wide: memory economics are violently cyclical (industry DRAM revenue swung +81% QoQ on contract-price spikes per the same TrendForce release), SK hynix holds the highest HBM bit-shipment mix among the top three (same release), and foundry trails TSMC 6.5% vs ~72% share (TrendForce data via TelecomLead, https://telecomlead.com/semiconductor/global-foundry-market-hits-record-47-95-bn-in-q1-2026-as-ai-chip-demand-drives-growth-tsmc-expands-share-to-72-126247). | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | wide Wide: the CUDA software platform and its developer installed base create high switching costs across the AI-training stack, defended by $76.7B cumulative R&D and reinforced by ~71% FY2026 gross margins and Data Center revenue (~90% of total) up 68% YoY — durable, hard-to-replicate advantages per the FY2026 10-K. |
| Moat type | cost scale The durable advantage is manufacturing scale and capital intensity: the top three DRAM suppliers take roughly $8.97 of every $10 of industry revenue (Samsung 38.5% + SK hynix 28.8% + Micron 22.4% in Q1 2026 per TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), a structure sustained by multi-billion-dollar fab economics that has admitted no new large entrant in decades; Samsung is the largest-revenue producer in both DRAM and NAND (TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html). | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip The durable edge rests on proprietary IP and software: the full-stack CUDA development platform running on all NVIDIA GPUs plus hundreds of proprietary domain libraries/SDKs/APIs, and $76.7B cumulative R&D yielding "inventions that are essential to modern computing" (NVIDIA invented the GPU in 1999). This is reinforced by developer-ecosystem network effects and CUDA switching costs, per the FY2026 10-K Business section. |
| Leadership | co leader Revenue leader in DRAM (38.5%) and NAND (31.6%) in Q1 2026 (TrendForce) and #1 in Q2 2026 smartphone shipments (Counterpoint), but not the leader where AI value concentrates: SK hynix has the highest HBM bit-shipment mix among the top three DRAM suppliers (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) and TSMC dominates foundry with ~72% share to Samsung's 6.5% (TrendForce via TelecomLead). | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | clear leader FY2026 Data Center revenue was $193.7B (~90% of the $215.9B total), up 68% YoY on the Blackwell ramp, and NVIDIA describes itself as "a data center scale AI infrastructure company reshaping all industries." The 10-K frames named rivals as parties who "provide or intend to provide" GPUs/accelerators — incumbent-leader positioning. |
| Pricing power | moderate Current pricing is extraordinary but cyclical, not structural: conventional DRAM contract prices rose roughly 93-98% QoQ in Q1 2026 (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) — shortage-driven commodity pricing that reverses in downcycles. The set-side shows the limit: Samsung's own MX (smartphone) division posted a KRW 0.7 trillion operating loss in Q2 2026 on elevated component costs (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | strong FY2026 gross margin was 71.1% (75.0% in FY2025); per the 10-K MD&A the ~3.9pt decline reflects the Hopper HGX→Blackwell full-system mix shift and a one-time $4.5B H20 excess-inventory/purchase-obligation charge, not competitive price erosion. A low-70s% hardware gross margin evidences strong pricing power. |
| Summary | Samsung Electronics is the world's largest memory maker and a vertically integrated device company. In Q1 2026 it was #1 in DRAM (38.5% revenue share) and #1 in NAND (31.6%), and in Q2 2026 it retook #1 in global smartphones at 24% share. The AI-datacenter memory shortage produced record results: Q2 2026 company revenue of KRW 171.5 trillion and an all-time-high operating profit of KRW 89.5 trillion, with server memory reaching a record share of the sales mix and HBM4E samples shipped to major customers (Samsung Newsroom). The caveats that keep the moat narrow: the profit pool is a price cycle, not a structural annuity; SK hynix leads the highest-value HBM segment by bit-shipment mix; and Samsung Foundry, at 6.5% share versus TSMC's ~72%, remains a distant second in leading-edge logic despite expanding 2nm design wins. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | NVIDIA pairs market-leading accelerated-computing hardware (the Blackwell data-center platform) with a proprietary full-stack software moat — CUDA plus hundreds of domain libraries — funded by $76.7B of cumulative R&D, and its "large and growing number of developers and installed base... strengthens our ecosystem and increases the value of our platform for our customers" (FY2026 10-K). Competition is intensifying from AMD, Intel and Huawei, and from hyperscalers (Alphabet, Amazon, Microsoft) designing internal AI silicon, but rivals must overcome NVIDIA's entrenched CUDA software ecosystem to displace it. |
| Chain position | Upstream supplier of DRAM/HBM and NAND to the AI datacenter buildout (server memory at a record share of its Q2 2026 sales mix; HBM4E samples shipped to major customers) and a contract foundry, while simultaneously a downstream device maker (Galaxy) that consumes its own components (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Upstream compute-platform supplier: NVIDIA sells full-stack data-center systems (GPU + Arm CPU + DPU + NVLink/InfiniBand networking + CUDA software) to cloud providers and enterprises, and relies on third-party foundry/assembly-test-packaging partners (e.g., SPIL, Amkor, Wistron, Fabrinet). Per the FY2026 10-K, several of its largest customers (hyperscalers such as Amazon, Alphabet, Microsoft) are simultaneously customers and emerging competitors developing internal accelerated-computing silicon. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.42 at weight 0.20 · swarm bullish Editorial prior, not backtested. |